| Document |
Document Title |
|
WO/2015/191752A1 |
The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein W, B, n, m, A', R1, R2, and R3 are described herein. The compounds are inhibitors to th...
|
|
WO/2015/190489A1 |
The purpose of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention pertains to a compound represented by general formula (IA): (the symbols in the formula are as stated in the s...
|
|
WO/2015/188073A1 |
This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.
|
|
WO/2015/182686A1 |
The present invention addresses the problem of providing a medicinal composition and, in particular, a compound suitable for treating nocturia. Under the expectation that nocturnal urinary frequency could be reduced via an antidiuretic a...
|
|
WO/2015/181470A1 |
The invention relates mainly to a method for producing a composition of glycidyl ethers synthesised from furan derivatives (furan glycidyl ethers), partly characterised by azeotropic distillation performed under reduced pressure and with...
|
|
WO/2015/177083A1 |
The invention belongs to the fields of pharmaceutical industry, and particularly to an improved stereoselective synthesis of intermediate compounds for the preparation of gliflozins, for example canagliflozin or structurally similar glif...
|
|
WO/2015/174695A1 |
The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (SGLTs) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate...
|
|
WO/2015/169854A1 |
The invention provides a method for the preparation of regioisomerically pure intermediates which are useful for the preparation of carboxy-fluorescein-type compounds. Such compounds have broad applications within bio-conjugation and/or ...
|
|
WO/2015/169412A1 |
The invention relates to carbazole, dibenzofurane, dibenzothiophene and fluorene derivatives which are substituted with electron-deficient heteroaryl groups, in particular for use as triplet matrix materials in organic light emitting dev...
|
|
WO/2015/167199A1 |
The present invention relates to an electron transport material and an organic electroluminescent device comprising the material in an electron transport layer. Tthe compounds according to the present invention as an organic electron tra...
|
|
WO/2015/160772A1 |
The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, R6, R7, R8, X, Z1and Z2 are defined in the specification.
|
|
WO/2015/158908A1 |
The present invention relates to small molecule compounds and their use in the treatment of diseases, in particular viral diseases, in particular hepatitis C virus (HCV).
|
|
WO/2015/158206A1 |
A C-aryl indican derivative represented by formula (I), and a pharmaceutical composition thereof and a preparation method therefor, as well as uses of the C-aryl indican derivative and a pharmaceutically acceptable salt or pharmaceutical...
|
|
WO/2015/158426A1 |
The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis ...
|
|
WO/2015/156417A1 |
The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases ...
|
|
WO/2015/144282A1 |
The invention relates to an inorganic-organic hybrid compound as an ion compound, composed of an inorganic cation and an organic anion active substance and optionally, an organic anion fluorescent dye.
|
|
WO/2015/143185A1 |
Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amy...
|
|
WO/2015/129782A1 |
Provided is a selective EP2 agonist exhibiting excellent safety. A compound represented by general formula (I) (all the symbols in general formula (I) are as indicated in the description), a salt thereof, an N-oxide thereof, solvates of ...
|
|
WO/2015/123722A1 |
This invention relates to compounds of the formula (I):The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the...
|
|
WO/2015/123595A1 |
Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine r...
|
|
WO/2015/117202A1 |
The present invention relates broadly to anti-cancer agents. In particular, the present invention relates to selected benzopyran compounds, the preparation thereof, and their use in methods for treating cancer and reducing the incidence ...
|
|
WO/2015/115507A1 |
Provided is a compound represented by formula (I) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof. This compound has an excellent TRPA1 antagonistic activity, which makes it possible t...
|
|
WO/2015/113455A1 |
The invention provides fluorogenic compounds and probes that can be used as reagents for measuring, detecting and/or screening superoxide. The fluorogenic compounds of the invention can produce fluorescence colors, such as green, yellow,...
|
|
WO/2015/114660A1 |
The present invention relates to novel compounds of the general formula (I), which are selective and peripherally acting KOR agonist, their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, their pharmaceu...
|
|
WO/2015/115613A1 |
The present invention provides: a good balanced resist which has high sensitivity without deteriorating basic physical properties of a chemically amplified resist such as resolution and line edge roughness (LER); and a compound for resis...
|
|
WO/2015/112754A1 |
Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, Z1, Z2, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or...
|
|
WO/2015/112445A1 |
Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, R3, R4, R5, R6, and X are as defined in the specification, are useful in treating conditions or disorders pre...
|
|
WO/2015/103756A1 |
The present invention provides compounds of Formula (I), and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the th...
|
|
WO/2015/104684A1 |
Disclosed are compounds having the formula (I): wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP...
|
|
WO/2015/104677A1 |
The present invention provides a compound of formula I, or an isotopic form, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, N-oxide or S-oxide thereof; and processes for their preparati...
|
|
WO/2015/103509A1 |
Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions ...
|
|
WO/2015/101916A1 |
An improved process for the preparation of empagliflozin is disclosed. Novel intermediates of formulas (13) and (14) for the preparation of empagliflozin are also disclosed, wherein R1 and R2 are independently hydrogen or hydroxyl protec...
|
|
WO/2015/100524A1 |
The present invention relates to a method for producing silymarin. The method comprises: pressing silybum marianum seeds to obtain silymarin powder, and soaking the silymarin powder by using alkaline water; extracting, by using acetone, ...
|
|
WO/2015/092610A1 |
The present invention relates to compounds of Formula (I) described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trk antagonists.
|
|
WO/2015/095767A1 |
Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a f...
|
|
WO/2015/084021A1 |
The present invention relates to a novel organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound according to the present invention can be used in a light-...
|
|
WO/2015/082642A1 |
Dental composite comprising (i) a polymerizable composition obtainable by reacting a mixture comprising: (a) x equivalents of one or more compounds of the following formula (I), wherein U is an (l+1)-valent hydrocarbon group which may co...
|
|
WO/2015/084796A1 |
Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof;. whereinRl,R2,R3,R4, R5, R6, Ql, Q2,yl, and Y2are as defined in the disclosure. Also disclosed are compositions containing the compounds of F...
|
|
WO/2015/074124A1 |
The present invention relates to anti-tropomyosin compounds, processes for their preparation, and methods for treating or preventing a proliferative disease, preferably cancer, using compounds of the invention.
|
|
WO/2015/074328A1 |
The present invention belongs to the technical field of organic chemistry, and specifically relates to a method for preparing rosuvastatin sodium. The method provided by the invention comprises: reducing 4-p-fluorophenyl-6-isopropyl-2-(N...
|
|
WO/2015/077193A1 |
There are disclosed compounds that are inhibitors of EZH2, pharmaceutical compositions containing said compounds and methods of treating hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases, utilizing...
|
|
WO/2015/065338A1 |
Compounds of Formula (I), wherein R1, R2, R3, R4 and n are defined herein, are useful as inhibitors of RSV.
|
|
WO/2015/062486A1 |
The present invention relates to biphenyl compounds and uses thereof in medicine. Specifically, the present invention relates to a compound of Formula (I), or a stereoisomer, a geometric isomer, a tautomer, a mesomer, a racemate, an enan...
|
|
WO/2015/061764A1 |
Disclosed herein plant propagation materials, methods of manufacturing, formulations and uses thereof. The plant propagation materials disclosed herein may comprise a strigolactone obtained by a biosynthetic process. The plant propagatio...
|
|
WO/2015/057205A1 |
The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease...
|
|
WO/2015/049535A1 |
The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to t...
|
|
WO/2015/048311A1 |
Pharmaceutical compositions described in this document comprise 5-(phenoxymethyl)-1,3-dioxane analogs having a disease-modifying action in the treatment of diseases associated with the production of cortisol that include metabolic syndro...
|
|
WO/2015/048065A1 |
Reactive extrusion can be used in a continuous, solvent-less preparation of imide oligomers involving two competing reactions among three ingredients, the first reaction between a dianhydride and a diamine and the second reaction between...
|
|
WO/2015/044229A1 |
The invention relates to new PI3K/AKT/m TOR inhibitors and their use for the prevention and/or the treatment of a disease selected from the group consisting of: inflammatory diseases, autoimmune diseases, neurodegenerative diseases, canc...
|
|
WO/2015/047113A1 |
The present invention relates to compounds of formula (I), and salts thereof and the pharmaceutical composition containing them in treatment of various diseases, as allergic rhinitis where R1 and R2 are, independently, hydrogen, halogen,...
|
